Streamlining Trelegy Prior Authorization for Oncology Patients and Beyond

The Dual Prior Authorization Challenge in Oncology Care

Oncology patients frequently present with complex health profiles, necessitating specialized cancer treatments alongside management of chronic conditions such as COPD or asthma. This creates a dual prior authorization challenge: securing approval for intricate oncology regimens while also managing PAs for essential supportive care and comorbidity medications like Trelegy.

Managing Trelegy Prior Authorization in a Complex Patient Population

Trelegy, a high-volume prior authorization target across commercial, Medicare Advantage, and Medicaid managed care plans, requires robust PA management. When prescribed for oncology patients with concurrent respiratory conditions, its authorization process must be integrated efficiently within a patient's overall complex care plan, avoiding delays that could impact quality of life or cancer treatment adherence.

The Intricacies of Oncology-Specific Prior Authorization

Oncology prior authorizations are among the most complex in healthcare, driven by high-cost biologics, infusion therapy, radiation oncology, and frequent regimen changes. A single patient may require dozens of PA events across diagnosis, staging, treatment initiation, changes, supportive care, and surveillance, making efficient management critical for timely care.

Critical Documentation for Oncology Treatment Approval

• Diagnosis confirmation: pathology report, tumor staging (AJCC TNM), relevant molecular markers (e.g., ER/PR/HER2, EGFR/ALK/PD-L1, BRCA, MSI/MMR).
• Prior-line treatment response and rationale for next line: documentation of previous regimens, response duration, and reason for change.
• Performance status: ECOG or Karnofsky score to support fitness for proposed treatment.
• Comorbidities and contraindications: organ function (creatinine, ejection fraction), prior toxicities relevant to the regimen.
• For off-label use: NCCN Compendium citation (Category 1, 2A, 2B) with specific tumor type and clinical context.

Common Prior Authorization Denial Reasons in Oncology

• Off-label use without NCCN Compendium support, especially when new evidence outpaces payer policy updates.
• Step therapy requirements, mandating failure or contraindication for less-costly alternatives.
• Documentation gaps: missing pathology subtype, prior-line response duration, or molecular marker results.
• Site-of-service mismatch for infusions (e.g., HOPD vs. freestanding infusion center).
• NCD/LCD non-coverage for Medicare Advantage plans, based on Original Medicare rules.

Klivira's Unified Platform for Concurrent PA Management

Klivira's platform is engineered to manage the full spectrum of prior authorization needs, from high-volume respiratory medications like Trelegy to complex oncology regimens. Our system provides NCCN-compendium-aware policy logic, regimen-level PA workflows, and concurrent PA tracking, ensuring comprehensive coverage for all patient needs, including those with comorbidities.

Navigating Medical and Pharmacy Benefit PAs for Oncology Patients

Oncology treatments often split between medical benefit (IV infusions, radiation) and pharmacy benefit (oral oncolytics, supportive care). Klivira effectively routes medical-benefit PAs via X12 278 or payer portals and pharmacy-benefit PAs through PBMs and ePA partners, ensuring seamless processing regardless of the benefit type for both cancer therapies and concurrent medications.